news & events
ysios news
16.03.18
Lundbeck to acquire Prexton Therapeutics adding foliglurax in clinical phase II to its pipeline of innovative treatments for patients suffering from Parkinson’s disease
31.01.18
QIAGEN enters into agreement to acquire STAT-Dx, plans to launch a next-generation, fully integrated multiplex platform for syndromic disease testing
15.11.17
Xeltis Closes €45 Million in Oversubscribed Series C Financing to Advance Aortic and Pulmonary Valve Programs
21.07.17
Kala Pharmaceuticals Announces Pricing of Initial Public Offering
30.06.17
Babyscripts Raises $5.7 Million to Build the Market’s Most Robust, Clinically-Validated Virtual Care Women’s Health Platform
23.05.17
Anaconda Biomed Secures 15 Million Euro in Series A Financing Led by Ysios Capital, Innogest Capital and Omega Funds.
04.05.17
Vivet Therapeutics raises €37.5 million in Series A financing round to advance novel gene therapies for treating inherited metabolic diseases
23.03.17
BioClin Therapeutics, Inc., Raises $30 Million in Series B Financing Led by Sofinnova Ventures and Ysios Capital
20.03.17
MedLumics Secures 34.4 Million Euros in Series B Funding
08.02.17
Prexton Therapeutics Series B financing round raises EUR 29 million (USD 31 million) to advance its novel Parkinson’s therapeutic
